The CD19 inhibitors landscape is experiencing significant transformation as researchers develop innovative strategies to selectively eliminate or control CD19-positive B cells across hematological cancers and immune-related conditions. CD19 has gained substantial attention as a therapeutic target due to its consistent expression throughout B-cell development and presence on many malignant B...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek